Hainan Kejin Biopharmaceutical

Hainan Kejin Biopharmaceutical is a Chinese pharmaceutical company specializing in the development and manufacture of biochemical and hemostatic drugs. The company is a leading producer of Hemocoagulase for Injection, marketed under the brand name Kesu, which is widely used in clinical settings to control bleeding during surgery and trauma. Founded in 1997 and based in Haikou, Hainan, the company was acquired by China Resources Double-Crane Pharmaceutical in 2012, becoming a key part of their specialized drug portfolio. Hainan Kejin operates modern GMP-certified production lines for small-volume injections and lyophilized powders. Its business focus remains primarily on the domestic Chinese market, leveraging its expertise in snake venom-derived enzyme purification.